Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory Renal medullary carcinoma
[vc_row][vc_column][vc_column_text css=""] Background: Some aggressive cancers have missing genes in their tumors, specifically SMARCB1 or SMARCA4. These types of tumors are often harder to treat and may not respond well to standard therapies. This study is testing two immunotherapy drugs: Tiragolumab blocks a protein called TIGIT, which activates the...
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
[vc_row][vc_column][vc_column_text css=""] Background: Past research has found that certain features of Wilms tumor—such as its size, biology, or response to treatment—can help predict the risk of relapse. Using this information, a variety of suitable chemotherapy drug combinations will be used in this study: Vincristine stops cancer cells from...
Stereotactic Radiation Therapy (SABR) With or Without Immunotherapy for Patients With Unresectable or Metastatic Kidney Cancer (SAMURAI)
[vc_row][vc_column][vc_column_text css=""] Background: Stereotactic body radiation therapy (SABR) is a type of radiation therapy that uses special equipment to deliver radiation to tumors with high precision. This method may kill tumor cells with few radiation doses over a shorter period, causing less damage to normal tissue. Immunotherapy, such...
A Study of BMS-986488 as Monotherapy and Combination Therapy in Patients with Advanced Malignant Tumors
[vc_row][vc_column][vc_column_text css=""] Background: BMS-986488 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Nivolumab (Opdivo®) is an immunotherapy that works by boosting the body's immune system to recognize and attack cancer cells. Since this...
A Study of MDNA11 Alone or in Combination with Pembrolizumab in Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. MDNA11 is an experimental cancer therapy that...
A Study of Combination Chemotherapy in Patients with Wilms Tumours
Background: Wilms tumour is a rare type of kidney cancer that primarily affects children. For most patients, the first line of treatment is surgery to remove the affected kidney (nephrectomy). This may be accompanied by either radiation treatment, chemotherapy, or both, depending on the size and...

























































